AIDSWEEKLY Plus; Monday, May 9, 2005
Staff Medical Writers

According to a recent report published in the journal Virology, "We analyzed the factors influencing the binding of polyclonal inummoglobutin (Ig)G from HIV-infected patients to primary isolates (PI) in capture assays and a potential correlation between this binding and neutralization.

"The fixation of antibodies (Abs) to viral particles was measured by quantifying the capture of 4 PI by purified IgG immobilized onto a plate or by analyzing the capture of IgG-virus complexes formed in solution."

"We found that the capture of virus and the formation of immune complexes is mainly achieved by Abs directed against the principal immunodominant domain (PID) of gp41.

"We have further compared the binding measured by these two methods and the neutralizing activity of our polyclonal IgG and found no correlation," said R. Burrer and coauthors at the University of Strasbourg.

"Thus, capture assays, including the immune complex capture assay that is more representative of 'physiological' conditions, cannot be used as a surrogate method for the investigation of the neutralizing activity of Abs," investigators concluded.

Burrer and colleagues published their study in Virology (Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41. Virology. 2005 Mar 1;333(1):102-13.

Additional information can be obtained by contacting C. Moog, University Strasbourg 1, Institute Virology, EA3770, 3 Rue Koeberle, F-67000 Strasbourg, France.

The publisher of the journal Virology can be contacted at: Academic Press Inc. Elsevier Science, 525 B St., Ste. 1900, San Diego, CA 92101-4495, USA.

Keywords: Strasbourg, France, Neutralization, HIV/AIDS, Immune Complex Formation, Immunology, Capture Assays.

This article was prepared by AIDS Weekly editors from staff and other reports.

Reference

Burrer R, Haessig-Einius S, et al., Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41, Virology. 2005 Mar 1;333(1):102-13.

PubMED Related articles Search

050509
AW050507

Copyright © 2005 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright © 1980,2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.